Ligand-dependent biosensors are valuable tools for coupling the intracellular concentrations of small molecules to easily detectable readouts such as absorbance, fluorescence, or cell growth. While ligand-dependent biosensors are widely used for monitoring the production of small molecules in engineered cells and for controlling or optimizing biosynthetic pathways, their application to directed evolution for biocatalysts remains underexplored. As a consequence, emerging continuous evolution technologies are rarely applied to biocatalyst evolution. Here, we develop a panel of ligand-dependent biosensors that can detect a range of small molecules. We demonstrate that these biosensors can link enzymatic activity to the production of an essential phage protein to enable biocatalyst-dependent phage-assisted continuous evolution (PACE) and phage-assisted continuous selection (PACS). By combining these phage-based evolution and library selection technologies, we demonstrate that we can evolve enzyme variants with improved and expanded catalytic properties. Finally, we show that the genetic diversity resulting from a highly mutated PACS library is enriched for active enzyme variants with altered substrate scope. These results lay the foundation for using phage-based continuous evolution and selection technologies to engineer biocatalysts with novel substrate scope and reactivity.
Ligand-dependent biosensors are valuable tools for coupling the intracellular concentrations of small molecules to easily detectable readouts such as absorbance, fluorescence, or cell growth. While ligand-dependent biosensors are widely used for monitoring the production of small molecules in engineered cells and for controlling or optimizing biosynthetic pathways, their application to directed evolution for biocatalysts remains underexplored. As a consequence, emerging continuous evolution technologies are rarely applied to biocatalyst evolution. Here, we develop a panel of ligand-dependent biosensors that can detect a range of small molecules. We demonstrate that these biosensors can link enzymatic activity to the production of an essential phage protein to enable biocatalyst-dependent phage-assisted continuous evolution (PACE) and phage-assisted continuous selection (PACS). By combining these phage-based evolution and library selection technologies, we demonstrate that we can evolve enzyme variants with improved and expanded catalytic properties. Finally, we show that the genetic diversity resulting from a highly mutated PACS library is enriched for active enzyme variants with altered substrate scope. These results lay the foundation for using phage-based continuous evolution and selection technologies to engineer biocatalysts with novel substrate scope and reactivity.
Enzymes
are increasingly valuable tools for chemical synthesis
due to their high catalytic proficiency and selectivity under mild,
environmentally friendly conditions.[1] Natural
enzymes can sometimes be repurposed as catalysts for synthesis, but
in most cases, enzymes with catalytic properties suitable for transformations
of interest cannot be readily obtained from nature.[2,3] Instead,
directed evolution, which involves iterative cycles of mutagenesis
followed by functional screening, can be used to improve enzyme activity,
substrate scope, stability, and selectivity.[4−9] Due to the slow speed and modest throughput of current enzyme directed
evolution pipelines, however, the potential for enzymes to impact
chemical synthesis is often limited.[10,11]In general,
modern enzyme engineering approaches involve some combination
of biochemical/bioinformatic analysis and/or genome mining to identify
a suitable parent enzyme and directed evolution to improve the activity
of interest in the parent enzyme.[12−14] These efforts are often
facilitated by automated systems that can typically assay enzyme library
sizes of ∼104 variants, but such systems are costly
to procure and maintain. Moreover, reprogramming enzymes to act on
new substrates or with new selectivity is often challenging because
the native activity and selectivity that make enzymes so attractive
in the first place often limit their scope toward non-native substrates.
In some cases, approaches such as substrate walking, in which enzymes
are evolved for activity on substrates with increasing structural
similarity to the target, can be used to gradually improve substrate
scope and activity, even under the constraints of limited library
screening throughput.[15−17] While substrate walking is effective, the time spent
developing activity for the related substrates is substantial and
slows the development of the target reaction. New technologies that
significantly increase the size of libraries that can be screened
and thus improve the speed of directed evolution could facilitate
the broader adoption of directed enzyme evolution for organic synthesis.In vivo continuous evolution has the potential
to dramatically accelerate directed evolution by eliminating manual
cycles of mutation, translation, selection, and replication required
by conventional directed evolution methods.[18−20] For example,
phage-assisted continuous evolution (PACE)[21,22] has been used to evolve novel function in proteases,[23,24] DNA-binding proteins,[25] T7 RNA polymerase
(T7 RNAP),[21,26−30] and a range of other enzyme classes[31−33] in a time span of only days-to-weeks without costly instrumentation
or user intervention. PACE involves linking the activity of a protein
of interest (POI), which has been encoded into the bacteriophage genome,
to the phage life cycle such that viral replication results in optimization
of the POI for the desired function. The link is established by a
biosensor system that modulates the production of pIII (encoded by gIII), a native bacteriophage protein essential for phage
replication, in response to POI function. Phage encoding the evolving
gene are propagated on a constant supply of Escherichia coli cells, which contain a plasmid for the expression of pIII and a
mutagenesis plasmid, added to a fixed volume vessel. Because the E. coli cells are continually added, and the system (the
“lagoon”)[21] is constantly
diluted, the E. coli cells do not have time to divide
before leaving the vessel and therefore cannot evolve. The rapid replication
time of phage allows multiple generations to propagate between lagoon
dilutions, ensuring that mutations are allowed to accumulate. With
a proper linkage between a carried gene of interest and an inducible
expression system for gIII, the phage replication
rate is dependent on the desired activity of interest. In other words,
phage harboring POI variants with improved function generate more
infectious progeny, leading to positive selection, while those encoding
inactive proteins cannot and are selected against. A related approach,
phage-assisted noncontinuous evolution (PANCE), was recently used
to evolve methanol dehydrogenase variants with 3.5-fold improved Vmax for the conversion of methanol to formaldehyde
via a ligand-dependent biosensor.[22,34] Despite this
promising result, the potential utility of biocatalyst evolution using
PACE or other in vivo directed evolution methods[35−39] is limited by the availability of biosensors, genetic circuits that
detect an input signal and drive a genetic output,[40] for a reaction product of interest.In this study,
we aimed to develop and validate selection systems
for the in vivo directed evolution of biocatalysts
using PACE and phage-assisted continuous selection (PACS). First,
to maximize the scope of products that can be detected and thus used
to drive PACE, we engineered a diverse set of ligand-dependent biosensors
capable of detecting a range of small molecules. Using a combination
of bacterial transcription factors, ligand-inducible regulators, and
chemically induced dimerization systems, we generated biosensing systems
for acrylate, IPTG, estrogen, and abscisic acid. We characterized
the sensitivity and specificity of each biosensor and then developed
each biosensor into a gene circuit that can drive phage replication
in response to enzyme catalysis (Figure a). Next, we developed a modified PACE apparatus
to allow for host cell preincubation with a small molecule substrate,
which is critical for biocatalyst evolution under the fast speed of
PACE. To validate the new approach, we demonstrate rapid, continuous
evolution of esterases. Moreover, we show that the same biosensor-driven
phage replication process involved in PACE enables PACS for the high-throughput
screening of esterase library variants (Figure b). These phage-assisted approaches provide
a powerful means to rapidly evolve and identify esterase variants
with improved properties for chemical synthesis. More broadly, this
study establishes workflows and a methodology needed to adopt PACE[21] and PACS[41] for a
range of other biocatalysts and reaction types.
Figure 1
In vivo continuous evolution approaches can be
far faster than conventional directed evolution methods and require
less human intervention, unlocking new chemical potential in enzymes.
(a) Overview of small-molecule-dependent PACE for the evolution of
selective biocatalysts. (b) Overview of small-molecule-dependent PACS
for the selection of selective biocatalysts.
In vivo continuous evolution approaches can be
far faster than conventional directed evolution methods and require
less human intervention, unlocking new chemical potential in enzymes.
(a) Overview of small-molecule-dependent PACE for the evolution of
selective biocatalysts. (b) Overview of small-molecule-dependent PACS
for the selection of selective biocatalysts.
Results
Developing
Biosensors for Biocatalyst PACE
Representative
ligand-dependent biosensors were selected based on their potential
applicability for an analysis of diverse substrates and reactions
and the availability of information regarding sensor performance (e.g.,
dynamic range, residual activity in the absence of inducer, sensitivity,
and cross-reactivity) (Figure a). Transcriptional repressors bind to a promoter sequence
and block RNA polymerase (RNAP) from transcribing a target gene. Transcription
is triggered when repressor proteins bind a ligand, affording an effective
sensor for specific and sensitive ligand detection.[42−44] AcuR, which
binds acrylate, was selected as a representative member of this family
due to its high dynamic range[45] and its
established utility for metabolic engineering applications.[46] The lacUV5 promoter, a mutated promoter from
the E. coli lac operon, is one of the most commonly
used promoters in molecular biology. It can drive high levels of gene
expression in response to isopropyl β-d-1-thiogalactopyranoside
(IPTG) and can be regulated by the LacI repressor.[47,48] Chemically induced dimerization systems utilize two proteins that
bind only in the presence of a ligand and have been extensively used
to identify protein–protein interactions and to control protein
localization.[49−51] The estrogen receptor and abscisic acid systems were
selected as representative ligand-inducible dimerization systems.
The human estrogen receptor ligand binding domain (LBD) and the SRC
coactivator receptor (RID) were identified by yeast two-hybrid data
as estradiol-dependent interacting proteins.[52−54] These domains
have been widely used to study estrogen signaling and have been engineered
to respond to different ligands. Similarly, the abscisic acid (ABA)
system relies on dimerization domains (ABI and PYL) that bind in the
presence of ABA.[29,55]
Figure 2
Development of biosensors for ligand detection.
(a) Ligands and
vector systems to link gIII expression and the presence
of small-molecule substrates. (b) Luciferase output of ligand-dependent
biosensors. E. coli expressing plasmids shown in
part a were incubated in the absence or presence of a small molecule
for 3 h and then analyzed for luminescence. (c) Phage replication
of ligand-dependent biosensors. E. coli expressing
plasmids shown in part a were incubated in the absence or presence
of ligand and phage for 6 h. Phage cultures were then collected and
analyzed for phage replication. Error bars are the standard deviation:
(b) n = 4 replicates and (c) n =
3 replicates.
Development of biosensors for ligand detection.
(a) Ligands and
vector systems to link gIII expression and the presence
of small-molecule substrates. (b) Luciferase output of ligand-dependent
biosensors. E. coli expressing plasmids shown in
part a were incubated in the absence or presence of a small molecule
for 3 h and then analyzed for luminescence. (c) Phage replication
of ligand-dependent biosensors. E. coli expressing
plasmids shown in part a were incubated in the absence or presence
of ligand and phage for 6 h. Phage cultures were then collected and
analyzed for phage replication. Error bars are the standard deviation:
(b) n = 4 replicates and (c) n =
3 replicates.The AcuR and lacUV5 biosensors
were each constructed as single
plasmids with the transcriptional repressor (AcuR) or inducible promoter
(lacUV5) and gIII translationally coupled to a bacterial
luciferase reporter system. The ligand-inducible dimerization systems
were fused to our previously developed split T7 RNAP (RNAP)[28] via flexible linkers. A functional RNAP is assembled
when the domains interact in the presence of ligand resulting in T7
promoter-driven expression of gIII and translationally
coupled luciferase. For each of these biosensors, the ribosomal binding
site sequences and plasmid copy number were optimized to provide low
background and high dynamic range (Figures S1–S4). The cross-reactivity of each sensor with our panel of probes (acrylate,
IPTG, estradiol, and ABA) was then examined using a luciferase reporter
assay (Figure b and Figure S5). All sensors responded to their cognate
ligands by at least 10-fold over the noncognate ligands examined.
The greatest orthogonality was observed with the ABA sensor which
responded ∼250-fold for ABA over the other probes. Phage growth
assays with each biosensor in the presence or absence of ligand were
then conducted (Figure c and Figure S6), and in each case, phage
growth was enhanced with the addition of a small molecule, demonstrating
that diverse biosensors can be used to link the presence of different
ligands to gIII expression.Each biosensor
was next evaluated against derivatives of its cognate
ligand to establish whether the sensors could be used to quantify
enzymatic reactions that reveal the ligand itself. A panel of derivatives
for each ligand was prepared, and the biosensor response was determined
by luciferase assay (Figure and Figure S7). Luciferase expression
was selective for the native ligand relative to the synthetic derivatives
in all cases. For example, RNAP assembly in response to ABA yielded
a robust luciferase signal (Figure d), while no induction was detected with ABA esters 4a–4e, highlighting the specificity of
the biosensor for the native ligand even over structurally similar
derivatives.
Figure 3
Small-molecule biosensors can be used to detect selective
biocatalysis.
(a) E. coli expressing the AcuR biosensor was incubated
in the absence or presence of acrylate esters or acrylate for 3 h
and then analyzed for luminescence. (b) E. coli expressing
the estradiol biosensor was incubated in the absence or presence of
methylated estradiol or estradiol for 3 h and then analyzed for luminescence.
(c) E. coli expressing the IPTG biosensor was incubated
in the absence or presence of IPTG esters or IPTG for 3 h and then
analyzed for luminescence. (d) E. coli expressing
the ABA biosensor was incubated in the absence or presence of ABA
esters or ABA for 3 h and then analyzed for luminescence. Error bars
are the standard deviation for n = 4 replicates.
Small-molecule biosensors can be used to detect selective
biocatalysis.
(a) E. coli expressing the AcuR biosensor was incubated
in the absence or presence of acrylate esters or acrylate for 3 h
and then analyzed for luminescence. (b) E. coli expressing
the estradiol biosensor was incubated in the absence or presence of
methylated estradiol or estradiol for 3 h and then analyzed for luminescence.
(c) E. coli expressing the IPTG biosensor was incubated
in the absence or presence of IPTG esters or IPTG for 3 h and then
analyzed for luminescence. (d) E. coli expressing
the ABA biosensor was incubated in the absence or presence of ABA
esters or ABA for 3 h and then analyzed for luminescence. Error bars
are the standard deviation for n = 4 replicates.
Given that the biosensors investigated could
link phage replication
to the presence of a specific ligand and that the ABA biosensor performed
well for the detection of ABA and not masked ABA esters, we aimed
to activate gIII expression via esterase-catalyzed
hydrolysis of substrates 4a–4e. In
general, esterases are versatile biocatalysts due to their stability
and compatibility with mild reaction conditions.[56] The exquisite stereoselectivity that can be achieved for
hydrolysis of some substrates has made esterases attractive for organic
synthesis.[56,57] However, naturally occurring
esterases may not possess suitable activity or enantioselectivity
for a desired transformation. We therefore aimed to develop a rapid
platform for esterase evolution to expand their utility for chemical
synthesis.BS2 esterase from Bacillus subtilis was selected as an initial evolution target since this enzyme and
several mutants have been efficiently expressed in E. coli and were shown to act on sterically hindered esters and tertiary
alcohols.[58−60] As a first step toward linking the phage life cycle
to ABA produced through esterase hydrolysis, BS2 activity on substrates 4a–4e was examined by HPLC (Figure a). BS2 efficiently catalyzed
the hydrolysis of 4a, but little or no activity was observed
on 4c or 4d. Based on these results, we
envisioned that 4a would act as a positive control (as
an efficiently hydrolyzed substrate of BS2) and could also be used
for a substrate walking approach in which improved activity on 4a is used as a first step to identify variants with activity
on 4c and 4d. To test the feasibility of
this approach, we aimed to detect replication of selection phage (SP)
expressing BS2 in the presence of the ABA derivatives. M13 phage were
engineered to replace gIII with BS2 and then combined
with host E. coli cells containing the ABA biosensor
in the presence of ABA, 4a–4d, or
no ligand. Phage growth was only detected with 4a or 4b and displayed a similar trend to BS2 activity (Figure b). These results
provide evidence that the ABA biosensor can link phage replication
to a ligand that is generated via BS2 hydrolysis of a precursor substrate.
Figure 4
Esterase-catalyzed
hydrolysis of abscisic acid (ABA) can support
phage replication. (a) BS2 activity on ABA esters. ABA esters (750
μM) were incubated with 5 μM BS2 over 60 min, and percent
conversion to ABA was determined. (b) BS2 phage replication with ABA
derivatives. Phage carrying BS2 were incubated with E. coli expressing ABA biosensor in the absence or presence of ABA esters
or ABA for 6 h. Phage cultures were then collected and analyzed for
phage replication. Error bars are the standard error for n = 3 replicates.
Esterase-catalyzed
hydrolysis of abscisic acid (ABA) can support
phage replication. (a) BS2 activity on ABA esters. ABA esters (750
μM) were incubated with 5 μM BS2 over 60 min, and percent
conversion to ABA was determined. (b) BS2 phage replication with ABA
derivatives. Phage carrying BS2 were incubated with E. coli expressing ABA biosensor in the absence or presence of ABA esters
or ABA for 6 h. Phage cultures were then collected and analyzed for
phage replication. Error bars are the standard error for n = 3 replicates.
Esterase Evolution Using
PACE
To initiate biocatalyst
PACE, we modified the conventional PACE setup to include a substrate
“holding tank” prior to the lagoon (Figure a,b). This addition allows
for preincubation of the host cells expressing the biosensor with
substrate to increase the likelihood of substrate entering the E. coli before being transferred to the lagoon containing
the SP (Figure S8). One holding tank can
seed up to four lagoons, which enables replicate evolution experiments
and reduces required substrate quantities. To validate this approach,
we conducted a mock PACE experiment to determine if active phage could
be enriched from an excess of inactive phage in the presence of 4a. A holding tank with 4a was assembled, and
a lagoon was seeded with 500-fold excess of active BS2 phage relative
to control phage that encode for human rhinovirus-14 (HRV) protease, which cannot process the esterase substrate and
should thus not replicate efficiently. Fresh E. coli host cells containing the ABA biosensor were continuously flowed
into the holding tank for incubation prior to entering the lagoon.
Phage samples were collected over time and assayed by PCR with primers
for the phage backbone to determine the relative HRV:BS2 population.
The BS2 phage population was detectable by PCR within 24 h and was
maintained in the lagoon over the next 24 h. In contrast, the HRV
population diluted out over the first 24 h, and complete washout of
the inactive phage was observed by 30 h (Figure c).
Figure 5
Evolution of esterase variants with activity
on ABA esters. (a)
Schematic of PACE for biocatalyst evolution. ABA derivative is preincubated
with E. coli expressing ABA biosensor 3 h prior to
transfer to a lagoon containing phage carrying BS2. Only BS2 phage
that can hydrolyze the derivative to ABA will be able to replicate
on the host cells and produce gIII to generate infectious progeny.
(b) Biocatalyst PACE setup with a holding tank for host cell preincubation
with ABA derivatives. (c) Phage competition in biocatalyst PACE. ABA
ester 4a was preincubated with host cells, and phage
carrying BS2 or HRV were mixed (1:500) as shown in part b. Phage samples
were collected 0–48 h after addition to the lagoon and then
analyzed by PCR. Bioconversions of BS2 and PACE BS2 variants on (d)
ABA ester 4a or (e) ABA ester 4b.
Evolution of esterase variants with activity
on ABA esters. (a)
Schematic of PACE for biocatalyst evolution. ABA derivative is preincubated
with E. coli expressing ABA biosensor 3 h prior to
transfer to a lagoon containing phage carrying BS2. Only BS2 phage
that can hydrolyze the derivative to ABA will be able to replicate
on the host cells and produce gIII to generate infectious progeny.
(b) Biocatalyst PACE setup with a holding tank for host cell preincubation
with ABA derivatives. (c) Phage competition in biocatalyst PACE. ABA
ester 4a was preincubated with host cells, and phage
carrying BS2 or HRV were mixed (1:500) as shown in part b. Phage samples
were collected 0–48 h after addition to the lagoon and then
analyzed by PCR. Bioconversions of BS2 and PACE BS2 variants on (d)
ABA ester 4a or (e) ABA ester 4b.Based on these results, we initiated PACE of BS2
to improve its
activity on substrate 4a. For the first 48 h, ABA was
also pumped into the lagoons (turning the sensor on) to determine
the efficiency of phage propagation and to provide an evolutionary
drift period. ABA was decreased over time and eventually completely
removed, such that only 4a was added to select for catalysis-dependent
evolution, and PACE was continued for an additional 48 h. BS2 variants
at the end of the experiments were subcloned into an arabinose-inducible
construct and assayed in E. coli with the ABA biosensor
(Figure a) for luciferase
output, which revealed that variants with improved catalytic performance
evolved during PACE (Figure S9). The top
four hits were selected and rescreened for activity using the HPLC
assay and confirmed up to 2-fold improved hydrolysis of 4a (Figure d).These four variants were then subjected to an additional round
of PACE with 4b to evolve enzymes with activity on a
more sterically hindered substrate. PACE was conducted using 4a and 4b for 48 h, followed by 4b alone for 72 h. The phage successfully replicated during the 5 days
of PACE, but no new mutations were detected in the BS2 population.
The same PACE experiment was conducted using phage expressing WT BS2,
and complete washout was observed, suggesting that the variants from
PACE using 4a had sufficient activity to survive on 4b. To support this idea, we confirmed that all four variants
had improved activity on 4b (Figure e). Further attempts to tune selection pressure
based on concentration of 4b and number of days on substrate
resulted in either no new mutations or phage extinction.While
our attempts to evolve BS2 via PACE were successful, the
overall improvements in catalytic activity were only 2-fold. We hypothesized
that the lack of functional improvement despite increased selection
pressure during PACE (e.g., by varying flow rate, substrate concentration,
mutagenesis rate, incubation time, etc.) and the low phage titers
observed (∼1 × 106 PFU/mL) could result from
a low effective library size under conditions that permitted phage
replication. We reasoned that phage-assisted continuous selection
(PACS)[41] could rectify this problem since
it allows for the use of in vitro mutagenesis strategies
while providing a powerful selection platform based on the same link
between POI function and phage replication required for PACE.
Esterase
Selection Using PACS
To establish the feasibility
of improving BS2 via PACS using the ABA biosensor, a library of BS2
variants was generated from WT BS2 and the four PACE variants noted
above via error prone PCR with a high error rate to ensure sampling
of as many unique variants as possible[61] (Figure S10). Aliquots of library phage
were cultured with an ester-caged fluorescein[62,63] to confirm that the library contained active variants, and significant
fluorescence was observed (Figure S11).
Biocatalyst PACS, which is identical to the PACE system except omitting
the mutagenesis plasmid, was then initiated with the BS2 library and 4b to enrich for variants with improved activity on 4b. After 24 h, the BS2 phage library was still able to replicate,
but a BS2 phage WT control showed phage extinction. Library phage
samples were then subcloned into a pET28 vector for expression in
BL21(λDE3) and subsequent screening for esterase hydrolysis
in lysate.Rapid qualitative analysis of 900 variants obtained
from BS2 PACS was conducted using MISER-MS (multiple injections in
a single experimental run).[64] 90 of the
top variants were reanalyzed by UHPLC, and 10 variants with at least
a 2-fold improvement over WT for the hydrolysis of 4b in lysate were identified (Figure S12). Variants 10D2 and 10D5 were particularly notable as they fully
hydrolyzed ester 4b in lysate. Sequencing revealed that
these variants (Table S2) had identical
genotypes and contained six new coding mutations, which would be a
very high number of mutations to emerge from a single round of traditional
directed evolution. These results confirm that PACS can be utilized
for the high-throughput screening of esterase library variants to
rapidly identify biocatalysts with improved activity.
Substrate Scope
of Evolved Esterases
A subset of esterases
with improved activity on 4b were purified and screened
against 4a–4d (Figure a,b and Figures S13–S17). For all enzymes except 10D2, the efficiency of the hydrolysis
is directly correlated to the steric bulk of the ester (Me > Et
≫
iPr, tBu). A steady state kinetic analysis of 10D2 showed that the
change in preference for bulkier esters is attributed to an increase
in KM for the methyl substrate 4a, which increases from 111 μM for WT BS2 to approximately 5615
μM for 10D2. KM for ethyl substrate 4b also increased from 143 to 1265 μM, but the compensatory
50-fold increase in Kcat results in a
more efficient reaction (Table S3).
Figure 6
Evaluation
of substrate scope for selected hits from a PACS screen.
(a) Reaction scheme for ABA esters evaluated. 750 μM substrate
was incubated with 5 μM BS2 variant for 1 h. (b) Conversion
of each reaction normalized to the WT reaction. Each bar represents
the average of three reactions. Yield of ABA obtained from a calibration
curve using 2-acetamidophenol as an internal standard (calibration
curve Figure S17). (c) Reaction scheme
for the hydrolysis of “truncated” ABA fragment, 3,3-dimethyl
acrylate (DMA) esters. 5 mM substrate was incubated with 10 μM
BS2 variant for 1 h. (d) Conversion of each reaction normalized to
the WT reaction. Each bar represents the average of three reactions.
Yield of 3,3-DMA obtained from a calibration curve using 5-bromoindole
as the internal standard (calibration curve Figure S18).
Evaluation
of substrate scope for selected hits from a PACS screen.
(a) Reaction scheme for ABA esters evaluated. 750 μM substrate
was incubated with 5 μM BS2 variant for 1 h. (b) Conversion
of each reaction normalized to the WT reaction. Each bar represents
the average of three reactions. Yield of ABA obtained from a calibration
curve using 2-acetamidophenol as an internal standard (calibration
curve Figure S17). (c) Reaction scheme
for the hydrolysis of “truncated” ABA fragment, 3,3-dimethyl
acrylate (DMA) esters. 5 mM substrate was incubated with 10 μM
BS2 variant for 1 h. (d) Conversion of each reaction normalized to
the WT reaction. Each bar represents the average of three reactions.
Yield of 3,3-DMA obtained from a calibration curve using 5-bromoindole
as the internal standard (calibration curve Figure S18).We also evaluated the activity
of our evolved esterases on several
structurally distinct substrates (5–8) protected with a simple 3,3-dimethyl acrylate (DMA) group in place
of the full ABA fragment (Figure c,d and Figure S18). Interestingly,
10D2 was found to have minimal activity on any of the other substrates
evaluated. In contrast, the two mutants found to be broadest in substrate
scope, 7A7 and 8F11, contain 4 (P90T, I130 V, N269S, L339P) and 3
(P76R, T220A, D320G) unique coding mutations, respectively. For 8F11,
which was over 2-fold improved over WT BS2 for hydrolysis of 6, all the mutations are found on the surface of the protein
far from the active site. This finding demonstrates that PACS is not
limited to improving activity on the substrate used for selection
and can give a population of active enzymes within which improved
activity for a variety of reactions can be found, as in another recently
reported example of continuous evolution for biocatalyst development.[36]Encouraged by the range of activity observed
in the substrate screen
using enzymes identified based on their activity on ABA esters, we
wanted to establish whether the PACS library might contain variants
with improved activity on DMA-protected substrates. WT-BS2 provided
low conversion of 5, for example, and none of the esterases
selected for activity on 4b showed significantly improved
activity on this substrate, making it an attractive challenge for
the library. The esterase compilation plate was screened against 5, and several enzymes were identified with improved conversion
relative to WT (Figure S19). One of these,
1E12 (I21M, K362E, P473M), was found to be 1.8-fold improved for the
hydrolysis of 5 over WT after IMAC purification, outperforming
any enzyme from the previously analyzed set (Figure S20).
Discussion
While directed evolution
has expanded the utility of biocatalysts,
relatively long times and significant instrumentation are generally
required for the evolution process.[10] Most
critically, limitations in library sizes often preclude dramatic enzyme
reprogramming efforts, thus limiting the potential of biocatalysts
to provide solutions to key problems in synthesis. Continuous directed
evolution can address these limitations by replacing the manual steps
in directed evolution with a continuous process in which enzyme evolution
and selection occur concurrently in host cells. PACE requires that
the activity of an evolving protein be linked to the production of
pIII, an essential protein for phage propagation. To address this
requirement for biocatalyst PACE, we established that various transcription
regulators would work as ligand-dependent biosensors and that different
modes of mutagenesis/selection are possible for enzyme evolution and
selection in phage-based systems.Despite extensive use of ligand-dependent
biosensors for detecting
small molecules in cells,[65−67] their use in assays for directed
evolution is rare,[68−70] and only one example of their use for continuous
evolution systems has been reported.[34] In
this study, we engineered multiple biosensors to detect diverse small-molecule
ligands and yield pIII or a reporter gene as an output. The sensor
designs included transcription factors, ligand-inducible promoters,
and dimerization systems, all of which responded robustly to their
cognate ligands. No response was observed for a panel of derivatives
of each ligand, indicating that the sensors can be used to detect
selective biocatalysts. Based on these sensors, P450 enzymes could
be screened for demethylase activity (methyl ether hydroxylation/acetal
hydrolysis) with methylated steroids[71] and
the estradiol sensor.[52] The ligands for
the remaining sensors were masked with esters for the detection of
esterase-catalyzed hydrolysis.[57] Continued
development of selective and sensitive ligand-dependent biosensors
could further expand continuous evolution of biocatalysts, enabling
further diversity of the substrates and reactions that could be accessed
via biocatalyst PACE or PACS.To initiate biocatalyst PACE,
we modified the conventional PACE
setup to include a holding tank for preincubation of the ligand derivative
and the host cells. While active BS2 phage could be enriched over
inactive phage, esterase PACE with the ABA biosensor and 4a–4b resulted in only up to a 2-fold improvement
in enzyme activity. Attempts to further improve enzyme activity by
modulating the selection pressure through ABA ester derivative concentration
or length of evolution on the substrate did not afford any new esterase
variants. This finding suggests that there is a window of biocatalyst
activity necessary for this PACE platform and that this approach may
be most useful for gaining functional variants rather than improved
variants. In contrast, a high-throughput screening of a BS2 phage
library with PACS rapidly selected biocatalysts with improved catalytic
activity. Variants 10D2 and 10D5, in particular, highlight the success
of PACS for a substrate walking approach, as significant activity
on 4c and 4d was detected while no activity
was observed on either substrate with WT BS2.A limitation of
evolving enzyme activity using model substrates
like 4a–4d is that improved activity
on the model substrate is often achieved at the expense of substrate
scope—activity on other substrates of interest. This issue
is particularly problematic when substrates are designed to release
fluorescent or (as in the current study) biologically active fragments
since those fragments are not found in typical organic substrates.
The low selection pressure in our PACS systems allows for “neutral
drift” of the enzyme,[72] where variants
with diminished activity on the target substrate are still allowed
to persist in the lagoon. Although these variants were not always
improved for the target substrate relative to WT, the presence of
this mild selection enriches the library in active mutants. We found
that screening these PACS-derived, functionally enriched libraries
for activity using substrate “mimics” that contain truncated
versions of the target substrate yielded enzymes that were significantly
improved for structurally distinct substrates.It is noteworthy
that, in both this study and the only previous
example of PACE applied to biocatalysis, it was necessary to modify
the standard PACE format to facilitate biocatalyst evolution. In our
study, low phage titers indicate low rates of phage replication in
the selection time frame (i.e., while E. coli is
circulating in the lagoon). These low phage titers correspond to a
small library size, and given the relatively low mutation rate observed
for the targeted gene, we suspect that sampling of the sequence space
to identify improved mutants was insufficient for the selection pressure
applied during PACE. The balance of tuning the “selection window”
such that selection pressure is high enough to require beneficial
mutation accumulation while ensuring the selection pressure is low
enough to allow for phage replication remains an issue in biocatalyst-dependent
PACE campaigns.
Conclusions
This study established
that gIII expression can
be linked to enzyme activity on small-molecule substrates to enable
enzyme optimization via PACE and PACS. In addition to expanding the
set of biosensor designs that have been linked to gIII expression, we demonstrated the potential of biocatalyst-dependent
PACE by evolving an esterase using a designed ABA biosensor. Moreover,
we developed a related PACS approach, leveraging the same genetic
tools, in conjunction with in vitro mutagenesis to
rapidly evaluate the activity of a large library of highly mutated
esterases. In addition to obtaining a mutant with 48-fold improvement
in kcat for the probe substrate, we showed
that the diverse enzymes obtained from the selection process can be
further screened to identify promiscuous activity. Many of the variants
identified contained mutations outside the esterase active site and
would have been missed by targeted mutagenesis approaches, and the
large number of mutations identified would have likely required multiple
rounds of conventional directed evolution to discover.We also
showed how a broader application of PACE for biocatalyst
evolution will require deepening our understanding of the “selection
window”. Despite the utility of PACE for evolving proteins
directly tied to gIII transcription or translation,
true continuous evolution of enzymatic activity on small molecules
using this platform remains challenging. This and another recently
published study[36] demonstrate that (semi)continuous
evolution platforms provide a powerful way to develop biocatalysts.
Recent improvements to the PACE methodology promise to not only increase
throughput but also further our understanding of the fundamental aspects
of continuous evolution. When compounding these advances with the
improvements to biosensor development and complementary methods of
substrate sequestration or substrate “sinks”,[73,74] the ability to apply new biosensors in directed evolution campaigns
is likely to play a significant role in the future of biocatalysis.
Authors: Chet M Berman; Louis J Papa; Samuel J Hendel; Christopher L Moore; Patreece H Suen; Alexander F Weickhardt; Ngoc-Duc Doan; Caiden M Kumar; Taco G Uil; Vincent L Butty; Robert C Hoeben; Matthew D Shoulders Journal: J Am Chem Soc Date: 2018-12-14 Impact factor: 15.419
Authors: Ahmed H Badran; Victor M Guzov; Qing Huai; Melissa M Kemp; Prashanth Vishwanath; Wendy Kain; Autumn M Nance; Artem Evdokimov; Farhad Moshiri; Keith H Turner; Ping Wang; Thomas Malvar; David R Liu Journal: Nature Date: 2016-04-27 Impact factor: 49.962